*Dear Editor,*

On 02 March 2020, a 36-year-old male came to the Emergency Department of Dr. Masih Daneshvari Hospital in Iran with a 3-day history of fever and dry cough. The patient was a physician with a history of close contact with COVID-19 cases. The patient had no underlying diseases and history of medicine usage.

Physical examination revealed a body temperature of 39°C, blood pressure of 120/70 mmHg, heart rate of 90 beats/minute, and peripheral oxygen saturation of 92%; he exhibited no dyspnea. Laboratory results revealed a white blood cell count of 5.81 cells/µL with 29.6% lymphocytes; no other abnormality was seen. The patient\'s swab specimen tested positive for COVID-19 by reverse transcription polymerase chain reaction (RT-PCR) on 04 March 2020 (cycle threshold value 22.39) [@bib0001]. Chest X-ray imaging revealed bilateral lower lobe infiltration ([Fig. 1](#fig0001){ref-type="fig"} a). Hence, the patient was diagnosed with COVID-19 pneumonia. The following were commenced: hydroxychloroquine 200 mg p.o. twice a day, oseltamivir 75 mg p.o. twice a day, lopinavir/ritonavir 200/50 mg p.o. in two tablets twice a day, and interferon β-1a 12 million units s.c. every other day.Fig. 1Chest X-ray of the patient during hospitalization. (a, b and c) Progression of lower and upper lobe infiltration. (d, e and f) Recovery of infiltration after tocilizumab administration.Figure 1

On 08 March 2020 the clinical condition of the patient deteriorated, and he exhibited dyspnea with an oxygen saturation of 85%. Fever and cough were persistent, and new chest X-ray imaging revealed progression of bilateral infiltration in the lower and upper lobes ([Fig. 1](#fig0001){ref-type="fig"}b). It was decided to initiate ribavirin 1,200 mg p.o. b.i.d. and immunoglobulin 20 mg i.v. daily. Meropenem and teicoplanin were also started to cover any probable bacterial sources. After 2 days, on 10 March 2020, his clinical condition worsened. Dyspnea continued with greater severity and he had an oxygen saturation of 83%. The ratio between the partial pressure of oxygen in arterial blood (PiO~2~) and the fraction of inspired oxygen decreased to 103 mmHg. Chest X-ray imaging did not show significant changes compared with the previous images ([Fig. 1](#fig0001){ref-type="fig"}c), and the patient was a candidate for intubation and invasive mechanical ventilation. However, this did not happen. Tocilizumab was considered as a last-chance therapy. The patient\'s IL-6 level was checked and it was \>200 pg/mL. QuantiFERON-TB testing was negative for *Mycobacterium tuberculosis*. Viral markers -- including hepatitis B virus, hepatitis C virus, and human immunodeficiency virus -- were reported negative. Hence, tocilizumab (Actemra Hoffmann-La Roche Limited) at a single dose of 400 mg was infused over 2 hours. The patient\'s vital signs were carefully checked during infusion to monitor any adverse effects.

After 2 days, the patient\'s dyspnea had gradually improved and his oxygen saturation increased to 90%. Chest X-ray imaging also showed less infiltration in comparison with previous imaging ([Fig. 1](#fig0001){ref-type="fig"}d). Recovery was observed over the next few days, and dyspnea and oxygen saturation significantly improved. The IL-6 levels were checked and found to have decreased from 200 pg/mL to 29 pg/mL and then decreased to 6 pg/mL within a few days. Lung infiltration had remarkably improved in subsequent chest X-ray imaging ([Fig. 1](#fig0001){ref-type="fig"}e and f). A swab specimen tested negative for COVID-19 by RT-PCR on 18 March 2020. After 18 days of hospitalization, the patient was discharged in an acceptable clinical condition. No bothersome dyspnea was noted, and oxygen saturation was 93% without supplemental oxygen. The timeline of vital signs, therapeutic regimens, and laboratory results are shown in [Fig. 2.](#fig0002){ref-type="fig"} Fig. 2Timeline of vital signs, therapeutic regimens, and laboratory results during hospitalization.Figure 2

Cytokine release syndrome may be the underlying pathophysiology in refractory cases of COVID-19. Tocilizumab is a recombinant humanized monoclonal antibody developed against soluble and membrane-bound IL-6 receptors. Tocilizumab prevents the binding of IL-6 to its receptors and reduces the activity of the cytokine by competing with both the soluble and membrane-bound forms of its receptors [@bib0002]. The current case was a refractory COVID-19 case who did not respond to conventional therapeutic agents and had tocilizumab administered as salvage therapy. In contrast to hydroxychloroquine, tocilizumab may be a useful agent in severe cases who have not responded to conventional therapy (chloroquine/hydroxychloroquine and antivirals) and those patients with elevated levels of IL-6 [@bib0003]. Successful management of tocilizumab was also reported in recent literature. Hammami et al. reported COVID-19 in a liver transplant recipient who responded to tocilizumab therapy [@bib0004]. The promising role of tocilizumab has also been reported in pilot studies. Improvements in respiratory and laboratory parameters were also observed in those studies \[[@bib0005],[@bib0006]\]. However, while tocilizumab is a promising agent against COVID-19, it is not an appropriate agent in patients with active or latent tuberculosis, bacterial and fungal infections, multi-organ failure, and gastrointestinal perforation [@bib0007].

In conclusion, tocilizumab may be considered a salvage therapeutic agent in COVID-19 patients who did not respond to other agents. Clinicians should be aware of the precautions and contraindications of tocilizumab, such as latent infection, and administer the drug with caution.
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